News and features

North Wales joins millions of participants worldwide for Terry Fox Run on 13 October. The Terry Fox Run UK raises funds for The Institute of Cancer Research, London. Wrexham, with the support of Ryan Reynolds, will become the first place in Wales to host a Terry Fox Run to honour Canadian hero Terry Fox.

Scientists have added to the list of inherited genetic mutations known to increase the risk of more aggressive prostate cancer.

The Institute of Cancer Research, London, congratulates the founders of the Chris Lucas Trust, our family charity partner, who are among those recognised in The King’s Birthday Honours List.

Kodiform Therapeutics, a new joint spin-out company from The Institute of Cancer Research, London, and the University of Oxford, has received a major seed funding investment from venture creation firm Oxford Science Enterprises.

Hundreds of thousands of people from across the country came together on Saturday to celebrate the life of the late Hairy Bakers TV star Dave Myers and raise thousands for our vital research.

A new type of liquid biopsy test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research by a team from The Institute of Cancer Research, London, has shown.

A spit test, where a sample can be collected at home, is more accurate at identifying future risk of prostate cancer for one group of men than the current standard blood test, a new study reports.

ICR researchers have identified the unique features of an exceptionally rare set of childhood brain tumours – a discovery that could pave the way for more effective treatments.

Killing breast cancer cells in a way that trains the immune system to recognise and destroy residual cancer cells could offer longer lasting protection to people with the disease.

Professor Axel Behrens, Scientific Director of the Cancer Research UK Convergence Science Centre and leader of the Cancer Stem Cell Group at The Institute of Cancer Research, London, has been awarded a prestigious Fellowship by the Academy of Medical Sciences.

Researchers at The Institute of Cancer Research, London, have increased our understanding of how a cancer drug called a PARP inhibitor stops working in women with breast cancer that has spread. This research could ultimately help predict who’s more likely to respond to these drugs, and could lead to more effective ways to treat the disease.

Radiotherapy can be used alongside hormone treatment, delaying the need for chemotherapy and therefore significantly protecting their quality of life for some patients with advanced prostate cancer, according to researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.